Loading patent…
AssigneeGeorgia State University Research Foundation, Inc. not for profit organization
InventorsDidier Merlin, Bo Xiao, Hamed Laroui
Estimating the term…
The present invention features, inter alia, constructs for the delivery of therapeutic and diagnostic agents to a patient. The constructs can include a nanoparticle, a targeting agent that specifically binds a targeted tissue or cell, a therapeutic moiety, and a hydrogel. The constructs can be used in the treatment and diagnosis of bowel diseases, including inflammatory bowel disease (IBD) and colon cancer. In one embodiment, the therapeutic agent is a nucleic acid that mediates RNA inhibition (RNAi), and the invention is directed to treatments for IBD that combine the positive aspects of such agents {e.g., siRNAs) with the safety of a biodegradable polymeric delivery system to facilitate specific targeting of colonic tissues and cells. As the constructs can be formulated for oral administration, they are well tolerated and offer advantages with regard to patient compliance.
A drug delivery vehicle, wherein the vehicle comprises a plurality of nanoparticles, a targeting agent that specifically binds a targeted tissue, a therapeutic moiety, and a hydrogel, wherein the targeting agent and the therapeutic moiety are associated with the nanoparticles, thereby forming a core, and the hydrogel is generally peripheral to the core.
-8. (canceled)
-12. (canceled)
(canceled)
(canceled)
-20. (canceled)
(canceled)
-28. (canceled)
(canceled)
-34. (canceled)
(canceled)
40-44. (canceled)
A diagnostic vehicle comprising a plurality of nanoparticles, a targeting agent that specifically binds colon cancer cells, a detectable moiety, and a hydrogel, wherein the targeting agent and the detectable moiety are associated with the nanoparticles, thereby forming a core, and the hydrogel is generally peripheral to the core.
(canceled)
(canceled)
Dependencies are inferred from the claim text.